Ethicon Inc. – a subsidiary of Johnson & Johnson – is recalling its Echelon Flex Endopath staplers because an out-of-spec component was used in the jaw of the device, leading to misshapen staples. It’s the second high-risk class I recall for Ethicon staplers this year.
The US Food and Drug Administration on 30 October classified yet another Ethicon Inc. surgical stapler recall as high-risk class I.
The firm, a subsidiary of Johnson & Johnson, is recalling its Echelon Flex Endopath staplers because an out-of-spec...
Create an account to read this article
Already a subscriber?
The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.
Philips Respironics has updated instructions for use for three ventilators that were included in a May 2024 recall. The company also added three potential injuries and one death to the original number.
The reason for the correction is that if the device momentarily activates but does not cut or staple tissue, providers can be inadvertently locked out during surgical procedures. When a lockout occurs, additional steps are required to open the device and remove it from tissue.
The US FDA says Baxter has notified customers about an issue with its Novum IQ Syringe Pump that is linked to two deaths and multiple injuries.
The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.
The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.
Hopes that last-minute negotiations might exempt Brazil’s $300m medtech exports from the latest round of US tariffs have been dashed, leaving the industry braced for further market instability that countermeasures could trigger.
